Hemostemix Inc.
HEM
株式のランク
#32564
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
株価
$0.04403621
最終同期: 2026-10-16
時価総額
$9.31M
変化（1日）
0.00%
変化（1年）
-40.80%
国
CA
取引 Hemostemix Inc. (HEM)
カテゴリー
Healthcare
の時価総額 Hemostemix Inc.(HEM)
時価総額: $9.31M
October 2026時点で、Hemostemix Inc. の時価総額は $9.31M です。これは、当社のデータによると、Hemostemix Inc. が世界で32564th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Hemostemix Inc. の時価総額の履歴（2005 から 2026 まで）
